ADVANCED MELANOMA

This study tests a new drug (brenetafusp) plus nivolumab against standard nivolumab treatments for people with a specific genetic type (HLA-A*02:01) who have advanced melanoma that hasn't been treated yet. About 680 participants will be enrolled to see if the combination helps de…

This phase 2 trial tests a new treatment called LM103 TILs for people with advanced melanoma that has not responded to at least two prior therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then infused back to attack the cancer. The…

This early-phase study tests a new approach for adults with advanced melanoma who are already on immunotherapy and scheduled for surgery. Participants receive focused ultrasound to heat and destroy part of their tumor, plus an injection of an experimental immune-boosting drug cal…

This early-phase study tests a new drug called AB821 in people with advanced melanoma or other solid tumors that respond to immunotherapy. The main goal is to check safety and find the right dose. About 50 adults will receive the drug every two weeks at Yale.

This study tests whether a combination of three drugs (fianlimab, cemiplimab, and ipilimumab) is safe and effective for people with advanced melanoma that has stopped responding to standard immunotherapy. About 88 adults with locally advanced or metastatic melanoma will receive t…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 participants will receive treatment based on their tumor's biomarkers. The goal is to see if this approach leads to a major or complete response …

This study tests whether adding the experimental drug EIK1001 to the standard immunotherapy pembrolizumab helps people with advanced melanoma live longer without their cancer growing. About 740 adults with stage 3 or 4 melanoma that cannot be removed by surgery will receive eithe…

This study tests a treatment made from a patient's own immune cells (called TILs) to fight advanced melanoma. Doctors take a sample of the tumor, grow the immune cells in a lab, and then put them back into the patient. The goal is to shrink tumors and control the cancer, but pati…

This early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like certain melanomas, ovarian, and uterine cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will t…

This early-phase study tests whether specially trained natural killer (NK) cells, given with two immunotherapy drugs (nivolumab and relatlimab), are safe and can shrink tumors in people with advanced melanoma that stopped responding to standard checkpoint inhibitors. About 33 adu…

This study tests a new treatment, T3011, in 42 people with advanced melanoma that has spread. The main goals are to check safety and see if tumors shrink. Participants must have measurable tumors and be in good overall health.

This early-phase study tests whether adding two common drugs—naltrexone and propranolol—to standard immunotherapy can safely help control advanced melanoma. The drugs target stress pathways that may weaken the immune system's ability to fight tumors. About 12 adults with advanced…

This study tests whether tebentafusp, alone or with pembrolizumab, helps people with advanced non-ocular melanoma live longer compared to standard treatments. It involves 540 adults whose tumors have a specific genetic marker (HLA-A*02:01) and have already tried other therapies. …

This study is testing a new drug called LBL-024, either alone or combined with other treatments (LBL-007 or toripalimab), in people with advanced melanoma that has spread. The goal is to see if these combinations can shrink tumors or slow the disease. About 200 adults will take p…

This study looks at whether high-intensity exercise and a high-fiber diet are possible and helpful for people with advanced melanoma who are receiving immunotherapy. The goal is to see if these lifestyle changes can improve gut health and immune function. The study will involve 4…

This early-phase study tests whether a new gold nanoparticle treatment (Au-TMP) is safe when injected into tumors, followed by radiation and an immunotherapy drug (Toripalimab). It involves 6 adults with advanced melanoma that cannot be surgically removed. The main goal is to che…

This Phase 3 study tests whether a new drug (vusolimogene oderparepvec) combined with an immunotherapy (nivolumab) works better than standard treatments for people with advanced melanoma that has worsened after prior anti-PD-1 and anti-CTLA-4 therapies. About 400 participants wil…

This study tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) for people with advanced melanoma who are already taking two others (nivolumab and relatlimab). About 90 adults with advanced or metas…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…